bioAffinity Technologies, Inc. — Form 8-K
Filed September 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 28/100
What the filing says
bioAffinity Technologies announced grant of Hong Kong Patent No. HK40048460 for its CyPath Lung noninvasive lung cancer diagnostic platform on September 17, 2026. The patent covers use of defined antibodies, porphyrin TCPP, and flow cytometry to detect lung cancer cells in sputum. Combined with a 2025 China patent, this strengthens IP protection in Asia, which accounts for ~1.6M annual lung cancer cases—a substantial potential market for the test.
Why this rating
Patent grant is positive but routine for biotech; no revenue, regulatory approval, or financial milestone. Material only if Asia commercialization succeeds—uncertain and distant.
See more from September 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.